Science News

Scientific Sessions 2019

November 16–18

Philadelphia, Pennsylvania

Late Breaking Science I – Outside the Box: New Approaches to CVD Risk Reduction

Innovative Strategies for Reducing Cardiovascular Risk

Joseph A. Hill, MD, PhD and Aruna Das Pradhan, MD, MPH discuss the trials presented in the first late breaking science session during Scientific Sessions 2019: DAPA-HF, ORION-10, COLCOT, BETonMACE.

John J V McMurray | BHF Cardiovascular Reseach Centre, Glasgow, United Kingdom

DAPA-HF: The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial: Results in Nondiabetic Patients
John J V McMurray | BHF Cardiovascular Research Centre, Glasgow, United Kingdom

  • RESULTS: In HFrEF patients both with and without T2DM, dapagliflozin + standard therapy reduced the risk of worsening HF events and CV death and improved symptoms.
  • See our special in-depth DAPA-HF page for slides, videos and commentary from this study
R. Scott Wright | Mayo Clinic, Rochester, MN

Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol - Results From the Phase 3 ORION-10 Trial
R. Scott Wright | Mayo Clinic, Rochester, MN

  • RESULTS: Twice-yearly inclisiran safely reduced LDL-C in ASCVD patients with continued high LDL-C while on maximum tolerated statin dose.
  • See our special in-depth ORION-10 page for slides, videos and commentary of this study
Jean-Claude Tardif | Montreal Heart Institute, Montreal, QC, Canada

The COLchicine Cardiovascular Outcomes Trial (COLCOT)
Jean-Claude Tardif | Montreal Heart Institute, Montreal, QC, Canada

  • RESULTS: Colchicine compared to placebo reduced the risk of ischemic CV events in patients with a recent MI.
  • See our special in-depth COLCOT page for slides, videos and commentary of this study
Kausik K Ray, Imperial College of London, London, United Kingdom

Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
Kausik K Ray, Imperial College of London, London, United Kingdom

  • RESULTS: In patients with ACS, DM, and low HDL-C, apabetalone, a selective BET protein inhibitor, did not significantly improve CV outcomes. CV outcomes trend was favorable.
  • See our special in-depth BETonMACE page for slides, videos and commentary of this study

Late Breaking Science II – Results for the Ischemia Trials: To Intervene or Not to Intervene

The ISCHEMIA Trials

Elliott Antman, MD, Alice Jacobs, MD, and John Spertus, MD, MPH discuss the significance of the results of the three highly anticipated ISCHEMIA trials which were presented during Scientific Sessions 2019.

Judith S Hochman | NYU School of Medicine, New York, NY; ISCHEMIA Research Group

ISCHEMIA - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes
Judith S Hochman | NYU School of Medicine, New York, NY; ISCHEMIA Research Group

  • RESULTS: In SIHD patients with moderate-severe ischemia, initial revascularization + OMT compared to OMT alone did not reduce the risk for adverse CV outcomes.
  • See our special in-depth ISCHEMIA page for slides, videos and commentary of this study
Sripal Bangalore| New York University School of Medicine, New York, NY; ISCHEMIA-CKD Research Group

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches- Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes
Sripal Bangalore| New York University School of Medicine, New York, NY; ISCHEMIA-CKD Research Group

  • RESULTS: In SIHD patients with moderate-severe ischemia and CKD, the risk of adverse clinical outcomes with an initial invasive strategy was not reduced compared to an initial conservative OMT strategy.
  • See our special in-depth ISCHEMIA-CKD page for slides, videos and commentary of this study

Late Breaking Science III — Controversies in Contemporary Management of AS

Sripal Bangalore| New York University School of Medicine, New York, NY; ISCHEMIA-CKD Research Group

Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results
George Dangas | Mount Sinai Hospital, New York, NY

  • RESULTS: More complications were seen with rivaroxaban-based vs antiplatelet-based antithrombotic therapy after TAVR in patients without an established indication for anticoagulation. Study suggests routine anticoagulation with rivaroxaban after TAVR not needed in the absence of another specific indication. Future trials needed.
  • See our special in-depth GALILEO page for slides, videos and commentary of this study
Ole De Backer | Rigshospitalet University Hospital, Copenhagen, Denmark

Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves (GALILEO-4D)
Ole De Backer | Rigshospitalet University Hospital, Copenhagen, Denmark

Ole De Backer | Rigshospitalet University Hospital, Copenhagen, Denmark

Balloon-Expandable versus Self-Expandable TAVR on Paravalvular Regurgitation and 2-Year Mortality: A Propensity-Matched Comparison From the FRANCE-TAVI Registry
Eric Van Belle | Institute Coeur Poumon - CHU Lille, Lille, France

Duk-Hyun Kang | Asan Medical Center, Seoul, Republic of Korea

RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis
Duk-Hyun Kang | Asan Medical Center, Seoul, Republic of Korea

  • RESULTS: Composite and all-cause death were lower with early surgery versus conventional treatment for asymptomatic, severe AS.
  • See our special in-depth RECOVERY page for slides, stats and background of this study

More science from Friday and Saturday

AHA News article: AHA tackles youth vaping crisis with massive new initiative – Learn about the $20 million End the Lies Youth Vaping and Nicotine Research Initiative to drive scientific discovery to help end teen vaping

AHA News article: E-cigarettes match traditional smoking in some heart risks

AHA News article: Flu shot may aid heart bypass recovery


More science:

Late Breaking Science IV – State of the Art Interventional Management for ACS Patients


State of the Art interventional Management for ACS Patients

J. Dawn Abbott, MD, provides an overview of the science presented during a late-breaking session that examined new and trending interventions for acute coronary syndrome. Dr. Abbott looks at COACT, OCT COMPLETE, and PCI with different kinds of heart pumps.


NHLBI-funded Research at Scientific Sessions 2019: COLCOT, ISCHEMIA, FUEL

Donald M. Lloyd-Jones, MD and David C. Goff, Jr, MD, Director, Division of Cardiovascular Sciences, NHLBI, NIH discuss implementation of a new NHLBI strategic plan for cardiovascular science and some of the NHLBI-funded research presented during Scientific Sessions 2019.

Usman Baber, Icahn School of Medicine at Mount Sinai, New York, NY

TWILIGHT-ACS: Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention for Acute Coronary Syndrome
Usman Baber | Icahn School of Medicine at Mount Sinai, New York, NY

Binita Shah | VA NY Harbor Healthcare System, NYU School of Medicine, New York, NY

Colchicine in Percutaneous Coronary Intervention
Binita Shah | VA NY Harbor Healthcare System, NYU School of Medicine, New York, NY

  • RESULTS: Pre-PCI colchicine reduced post PCI inflammation but not the risk of PCI-related myocardial injury.
  • See our special in-depth Colchicine-PCI page for slides, videos and commentary of this study
Natalia Pinilla Echeverri | McMaster University, Hamilton, ON, Canada

OCT COMPLETE: Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography
Natalia Pinilla Echeverri | McMaster University, Hamilton, ON, Canada

Jorrit Lemkes | Amsterdam University Medical Center, Amsterdam, Netherlands

COACT: One Year Outcomes of Coronary Angiography After Cardiac Arrest
Jorrit Lemkes | Amsterdam University Medical Center, Amsterdam, Netherlands

Sanket Dhruva | UCSF School of Medicine, San Francisco, CA

Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella™ vs Intra-Aortic Balloon Pump
Sanket Dhruva | UCSF School of Medicine, San Francisco, CA

Amit P Amin | Washington University School of Medicine, Saint Louis, MO

Comparative Effectiveness and Costs of Impella versus Intra-aortic Balloon Pump in the United States
Amit P Amin | Washington University School of Medicine, Saint Louis, MO

Presidential Session

Presidential Session 2019 - Harrington introduction

The session featured AHA President Bob Harrington, MD, AHA CEO Nancy Brown and Muratz Sönmez, World Economic Forum managing board member. Read session highlights.

Presidential Session 2019 - Distinguished Scientists

The 2019 recipients of the AHA Distinguished Scientists Award are recognized for their years of scientific excellence to the cardiovascular community.

Late Breaking Science V – Challenges in Heart Failure Management


Challenges in Heart Failure Management

Clyde Yancy, MD, Ileana Piña, MD, and Lynne Warner Stevenson, MD discuss some of the challenges posed by the results of the late breaking heart failure science presented during Scientific Sessions 2019.

David J Goldberg, Children's Hospital of Philadelphia, Philadelphia, PA

FUEL - Results From the Pediatric Heart Network’s Fontan Udenafil Exercise Longitudinal Trial
David J Goldberg, Children's Hospital of Philadelphia, Philadelphia, PA

Felipe Martinez |Insto Damic, Cordoba, Argentina

Effect of Treatment According to Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
Felipe Martinez |Insto Damic, Cordoba, Argentina

Mikhail Kosiborod | St. Luke's Health System, Kansas City, MO

Effect of treatment measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
Mikhail Kosiborod | St. Luke's Health System, Kansas City, MO

PARAGON-HF: LBCT: Effects of Sacubitril/Valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction
John J McMurray | University of Glasgow, Glasgow, United Kingdom

Scott D Solomon, Brigham and Womens Hospital, Boston, MA

PARAGON-HF Secondary Analysis: Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D Solomon, Brigham and Women's Hospital, Boston, MA

Late Breaking Science VI – New Frontiers in Lipid Therapy


New Frontiers in Lipid Therapy

Jennifer Robinson, MD, MPH, Alan Brown, MD, and Samia Mora, MD discuss the clinical implications of the results of the late breaking lipid therapy trials presented during Scientific Sessions 2109.

Matthew J Budoff | Lundquist Institute and UCLA School of Medicine, Torrance, CA

EVAPORATE: Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200-499mg/dl) on Statin Therapy
Matthew J Budoff | Lundquist Institute and UCLA School of Medicine, Torrance, CA

Frederick J Raal | Johannesburg Hospital, Johannesburg, South Africa

Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial
Frederick J Raal | Johannesburg Hospital, Johannesburg, South Africa

  • RESULTS: In patients with heterozygous familial hypercholesterolemia and on maximally tolerated statin dose, twice-yearly inclisiran safely reduced LDL-C approximately 50%.
  • See our special in-depth ORION-9 page for slides, videos and commentary of this study
Christie M Ballantyne | Baylor College of Medicine, Houston, TX

RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides
Christie M Ballantyne | Baylor College of Medicine, Houston, TX

Gerald F Watts | University of Western Australia, Royal Perth Hospital, Perth, Australia

RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects
Gerald F Watts | University of Western Australia, Royal Perth Hospital, Perth, Australia

Pierre Amarenco | Paris University, Paris, France

Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After an Ischemic Stroke of Atherosclerotic Origin, the Treat Stroke to Target Trial Results
Pierre Amarenco | Paris University, Paris, France

  • RESULTS: Following an atherosclerotic ischemic stroke, reducing LDL-C to <70 mg/dL compared to 100±10 mg/dL resulted in lower risk for more CV events.
  • See our special in-depth Treat Stroke to Target page for slides, videos and commentary of this study